1.

Record Nr.

UNINA9910300201603321

Titolo

Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development : A Focus on Early Phase Clinical Studies / / edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch

Pubbl/distr/stampa

London : , : Springer London : , : Imprint : Springer, , 2015

ISBN

1-4471-4920-3

Edizione

[1st ed. 2015.]

Descrizione fisica

1 online resource (316 p.)

Disciplina

610

615

615.19

616

616.39

616.46

616462

Soggetti

Medicine

Internal medicine

Diabetes

Metabolic diseases

Pharmacology

Pharmaceutical technology

Medicine/Public Health, general

Internal Medicine

Metabolic Diseases

Pharmacology/Toxicology

Pharmaceutical Sciences/Technology

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references at the end of each chapters and index.

Nota di contenuto

1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4.



Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9.  Assessment of cardiovascular safety of new diabetes drugs.

Sommario/riassunto

This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development.  Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development  will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.